Pharmacy alerts
-
Valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival, and Syonell): review by two specialists required for male patients
Drug safety update: The MHRA has published a drug safety update on the requirements for initiating valprote products.
-
Original pack dispensing
From 1 January 2025, NHS community pharmacists and their teams can dispense up to 10% more or less than the quantity prescribed of eligible medicines on NHS prescriptions if it means the medicine can be dispensed in the manufacturer’s original packaging and if they follow the prescriber’s directions on the prescription. The regulations on what types of prescriptions can be dispensed or reimbursed differ between England, Scotland and Wales. Please read our guidance or check Community Pharmacy England, Community Pharmacy Scotland and Community Pharmacy Wales for more information on what the new rules apply to. Our guidance covers the changes, what the rules apply to, steps to use professional judgment and additional considerations. The guidance can be found on the RCPharm website.
-
Pancreatic enzyme replacement therapy (PERT) NatPSA/2024/013/DHSC shortage
Patient Safety Alert: The MHRA has published an additional Patient Safety Alert on the shortage of pancreatic enzyme replacement therapy (PERT) NatPSA/2024/013/DHSC.
-
Indefinite ban on the supply of puberty blockers
To children and young people under 18 years of age.
-
Legislative changes to widen access to naloxone
Following a consultation by the Department of Health and Social Care (DHSC), the Human Medicines Regulations (2012) (HMR) have been changed to widen access to naloxone. These changes come into force today (2 December 2024).
-
Lexon UK Ltd, Moclobemide 150mg tablets defect
Class 4 medicines defect notification: The MHRA has published a Class 4 medicines defect notification for moclobemide 150mg tablets.